Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritisMurat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, Fabian Proft, Mikhail Protopopov, Maryna Verba, Judith Rademacher, Hildrun Haibel, Joachim Sieper, Martin Rudwaleit, Denis Poddubnyy
11 August 2022
Factors predicting axial spondyloarthritis among first-degree relatives of probands with ankylosing spondylitis: a family study spanning 35 yearsSjef M van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Kazim Khan, Peter M Villiger, Matthew A Brown
16 May 2022
Does biologic therapy impact the development of PsA among patients with psoriasis?Elana Meer, Joseph F Merola, Robert Fitzsimmons, Thorvardur Jon Love, Shiyu Wang, Daniel Shin, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Jose U Scher, C T Ritchlin, Joel M Gelfand, Alexis Ogdie
4 January 2022
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trialAnna Molto, Clementina López-Medina, Filip E Van den Bosch, Annelies Boonen, Casper Webers, Emanuelle Dernis, Floris A van Gaalen, Martin Soubrier, Pascal Claudepierre, Athan Baillet, Mirian Starmans-Kool, Anneke Spoorenberg, Peggy Jacques, Philippe Carron, Rik JoosSee the full list of authors
12 October 2021
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?Ulf Lindström, Karin Bengtsson, Tor Olofsson, Daniela Di Giuseppe, Bente Glintborg, Helena Forsblad-d'Elia, Lennart T H Jacobsson, Johan Askling
12 October 2021
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitisZhixiu Li, Xin Wu, Paul J Leo, Erika De Guzman, Nurullah Akkoc, Maxime Breban, Gary J Macfarlane, Mahdi Mahmoudi, Helena Marzo-Ortega, Lisa K Anderson, Lawrie Wheeler, Chung-Tei Chou, Andrew A Harrison, Simon Stebbings, Gareth T JonesSee the full list of authors
12 August 2021
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)Robert BM Landewé, Lianne S Gensler, Denis Poddubnyy, Proton Rahman, Maja Hojnik, Xiaoqi Li, Soyi Liu Leage, David Adams, Hilde Carlier, Filip Van den Bosch, , on behalf of the COAST-Y study group, Federico Javier Ariel, Alberto Berman, Judith CarrioSee the full list of authors
13 July 2021
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled studyAtul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, Xenofon Baraliakos, Lianne S Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S Kanik, Désirée van der Heijde
13 July 2021
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trialJames Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi, , 4827-006 study group, Kurisu Tada, Mitsumasa Kishimoto, Kou Katayama, Atsuo Taniguchi, Yohei Seto, Mitsuhiro Morita, Kazuhiro HattaSee the full list of authors
13 July 2021
Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitisZihao Li, Siwen Chen, Haowen Cui, Xiang Li, Dongying Chen, Wenjun Hao, Jianru Wang, Zemin Li, Zhaomin Zheng, Zhongping Zhang, Hui Liu
17 June 2021